The HIV immune response evolves during infection and may be impacted by factors such as antiretroviral treatment (ART). We used a massively-multiplexed system to profile the antibody (Ab) response to HIV infection in individuals with early to late stage infection and to evaluate the relationship between Ab diversity and ART initiation.
Ab profiles were analyzed with the VirScan assay. This assay uses phage immunoprecipitation sequencing to quantify Ab binding to >3,300 HIV peptides spanning the HIV genome. The analysis included 403 samples from 57 African women with known duration of HIV infection (14 days to 8.7 years). ART was started at a CD4 count <250 cells/mm[sup]3[/sup]; 32/57 women started ART during the study period (ART group). For each sample, network graphs were used to calculate the number of unique non-overlapping epitopes that had high levels of Ab binding (Ab breadth). We measured the change in Ab breadth 9-24 months after infection and compared time to ART initiation among those with declining vs. stable or increasing Ab breadth. We also analyzed the associations between the rate of change in Ab breadth over time, ART initiation, and other factors.
In most persons, Ab breadth increased during the first 6 months of infection. In the non-ART group, Ab breath reached a plateau (‘Ab breadth set point’) 9-12 months after infection. In the ART group, analysis using a Cox proportional hazards model showed that those who had stable or increasing Ab breadth 9-24 months after infection started ART later than those with decreasing Ab breadth (log-rank test for earlier ART initiation: p=0.009, hazards ratio: 0.29, 95% CI: 0.11, 0.78, p=0.014). A faster decline in Ab breadth was correlated with lower baseline CD4 cell count (p=0.002) and higher pre-ART viral load set point (p=0.001). Ab breadth stabilized after ART initiation at levels similar to those seen in early HIV infection.
Deep profiling of the antibody response to HIV infection identified a novel feature of the anti-HIV immune response, Ab breadth, that was associated with clinically-significant outcomes.